MET
MetLife, Inc. [MET] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
MET Stock Summary
Top MET Correlated Resources
MET
Top 10 Correlated ETFs
MET
Top 10 Correlated Stocks
MET
In the News
MET Financial details
MET Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 74.25 | 74.73 | 82.39 | 87.02 | 87.64 | |
| Net income per share | 6.29 | 5.96 | 7.95 | 2.93 | 2.08 | |
| Operating cash flow per share | 14.7 | 12.82 | 14.6 | 16.44 | 18.11 | |
| Free cash flow per share | 8.67 | 8.12 | 19.65 | 16.44 | 16.56 | |
| Cash per share | 371.45 | 416.95 | 425.98 | 375.88 | 406.62 | |
| Book value per share | 70.55 | 82.13 | 78.22 | 33.67 | 39.61 | |
| Tangible book value per share | 40.54 | 50.69 | 46.23 | -9.3 | 27.74 | |
| Share holders equity per share | 70.55 | 82.13 | 78.22 | 33.67 | 39.61 | |
| Interest debt per share | 18.99 | 21 | 21.27 | 23.55 | 26.23 | |
| Market cap | 47.79B | 42.62B | 53.91B | 58.13B | 50.11B | |
| Enterprise value | 48.04B | 40.98B | 51.29B | 55.91B | 48.3B | |
| P/E ratio | 8.1 | 7.88 | 7.86 | 24.69 | 31.75 | |
| Price to sales ratio | 0.69 | 0.63 | 0.76 | 0.83 | 0.75 | |
| POCF ratio | 3.47 | 3.66 | 4.28 | 4.4 | 3.65 | |
| PFCF ratio | 5.88 | 5.78 | 3.18 | 4.4 | 3.99 | |
| P/B Ratio | 0.72 | 0.57 | 0.8 | 2.15 | 1.67 | |
| PTB ratio | 0.72 | 0.57 | 0.8 | 2.15 | 1.67 | |
| EV to sales | 0.69 | 0.6 | 0.72 | 0.8 | 0.73 | |
| Enterprise value over EBITDA | 8.62 | 7.21 | 8.3 | 14.8 | 20.46 | |
| EV to operating cash flow | 3.48 | 3.52 | 4.07 | 4.23 | 3.52 | |
| EV to free cash flow | 5.91 | 5.56 | 3.03 | 4.23 | 3.85 | |
| Earnings yield | 0.12 | 0.13 | 0.13 | 0.04 | 0.03 | |
| Free cash flow yield | 0.17 | 0.17 | 0.31 | 0.23 | 0.25 | |
| Debt to equity | 0.25 | 0.24 | 0.26 | 0.66 | 0.63 | |
| Debt to assets | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | |
| Net debt to EBITDA | 0.05 | -0.29 | -0.42 | -0.59 | -0.77 | |
| Current ratio | 1.57K | 1.01K | 1.13K | 1.37K | 977.51 | |
| Interest coverage | 5.18 | 5.55 | 5.96 | 3.31 | 1.57 | |
| Income quality | 2.33 | 2.15 | 1.92 | 5.16 | 8.56 | |
| Dividend Yield | 0.04 | 0.04 | 0.03 | 0.03 | 0.04 | |
| Payout ratio | 0.31 | 0.34 | 0.27 | 0.76 | 1.12 | |
| Sales general and administrative to revenue | 0.09 | 0.09 | 0.08 | 0.08 | 0.09 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Capex to operating cash flow | -0.41 | -0.37 | 0.35 | 0 | -0.09 | |
| Capex to revenue | -0.08 | -0.06 | 0.06 | 0 | -0.02 | |
| Capex to depreciation | -8.97 | -6.9 | 6.28 | 0 | -1.63 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 99.93 | 104.91 | 118.26 | 47.12 | 43.08 | |
| ROIC | 0.05 | 0.04 | 0.05 | 0.06 | 0.02 | |
| Return on tangible assets | 0.01 | 0.01 | 0.01 | 0 | 0 | |
| Graham Net | -364.41 | -394.76 | -393.12 | -403.74 | -500.89 | |
| Working capital | 368.48B | 395.99B | 384.49B | 296.76B | 301.74B | |
| Tangible asset value | 57.07B | 64.71B | 58.21B | 17.99B | 21.02B | |
| Net current asset value | -305.37B | -323.95B | -307.13B | -342.35B | -355.28B | |
| Invested capital | 0.25 | 0.24 | 0.26 | 0.66 | 0.63 | |
| Average receivables | 20.04B | 19.16B | 17.6B | 17.42B | 23.33B | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | -31.91B | -61.13B | -57.63B | -27.68B | -52.16B | |
| Days sales outstanding | 107.18 | 96.14 | 89.01 | 91.4 | 160.28 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 3.41 | 3.8 | 4.1 | 3.99 | 2.28 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.09 | 0.07 | 0.1 | 0.09 | 0.05 | |
| Capex per share | -6.03 | -4.7 | 5.05 | 0 | -1.54 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 20.81 | 19.85 | 21.7 | 21.12 | 26.04 | |
| Net income per share | 1.71 | 0.1 | 0.52 | 0.65 | 0.83 | |
| Operating cash flow per share | 3.23 | 2.61 | 3.97 | 4.62 | 7.09 | |
| Free cash flow per share | 3.23 | 2.61 | 4.98 | 5.19 | 6.57 | |
| Cash per share | 384.99 | 395.27 | 399.78 | 389.13 | 421.58 | |
| Book value per share | 34.48 | 41.52 | 39.51 | 34.15 | 41.07 | |
| Tangible book value per share | -9.52 | 3.96 | 1.8 | -3.93 | 28.76 | |
| Share holders equity per share | 34.48 | 41.52 | 39.51 | 34.15 | 41.07 | |
| Interest debt per share | 23.24 | 23.48 | 23.7 | 25.37 | 26.13 | |
| Market cap | 56.75B | 44.93B | 43.3B | 47.27B | 48.33B | |
| Enterprise value | 54.54B | 44.42B | 45.78B | 51.15B | 46.52B | |
| P/E ratio | 10.56 | 140.4 | 26.93 | 24.17 | 19.9 | |
| Price to sales ratio | 3.48 | 2.92 | 2.6 | 2.98 | 2.54 | |
| POCF ratio | 22.4 | 22.18 | 14.25 | 13.6 | 9.33 | |
| PFCF ratio | 22.4 | 22.18 | 11.36 | 12.13 | 10.07 | |
| P/B Ratio | 2.1 | 1.4 | 1.43 | 1.84 | 1.61 | |
| PTB ratio | 2.1 | 1.4 | 1.43 | 1.84 | 1.61 | |
| EV to sales | 3.34 | 2.89 | 2.75 | 3.22 | 2.44 | |
| Enterprise value over EBITDA | 27.66 | 87.61 | -232.38 | -655.83 | 57.57 | |
| EV to operating cash flow | 21.52 | 21.92 | 15.07 | 14.72 | 8.98 | |
| EV to free cash flow | 21.52 | 21.92 | 12.01 | 13.12 | 9.69 | |
| Earnings yield | 0.02 | 0 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0.04 | 0.05 | 0.09 | 0.08 | 0.1 | |
| Debt to equity | 0.66 | 0.56 | 0.59 | 0.73 | 0.63 | |
| Debt to assets | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Net debt to EBITDA | -1.12 | -1 | -12.6 | -49.79 | -2.24 | |
| Current ratio | 1.37K | 1.94K | 1.62K | 1.3K | 2.83K | |
| Interest coverage | 7.94 | 1.97 | -0.77 | -0.29 | 3 | |
| Income quality | 1.36 | 25.33 | 7.56 | 7.11 | 8.54 | |
| Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Payout ratio | 0.31 | 5.69 | 1.07 | 0.94 | 0.69 | |
| Sales general and administrative to revenue | 0.1 | 0.1 | 0.09 | 0.1 | 0.09 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Capex to operating cash flow | 0 | 0 | 0.25 | 0.12 | -0.07 | |
| Capex to revenue | 0 | 0 | 0.05 | 0.03 | -0.02 | |
| Capex to depreciation | 0 | 0 | 25.8 | 16.27 | 0 | |
| Stock based compensation to revenue | 0.01 | 0 | 0 | 0 | 0 | |
| Graham number | 36.45 | 9.82 | 21.6 | 22.36 | 27.7 | |
| ROIC | 0.03 | 0 | 0 | 0 | 0.01 | |
| Return on tangible assets | 0 | 0 | 0 | 0 | 0 | |
| Graham Net | -413.53 | -448.62 | -461.11 | -477.97 | -495.22 | |
| Working capital | 296.76B | 325.02B | 324.71B | 285.67B | 337.14B | |
| Tangible asset value | 17.99B | 23.04B | 21.23B | 16.79B | 21.02B | |
| Net current asset value | -342.35B | -316.66B | -321.87B | -340.33B | -320.07B | |
| Invested capital | 0.66 | 0.56 | 0.59 | 0.73 | 0.63 | |
| Average receivables | 17.68B | 18.1B | 18.71B | 18.86B | 24.08B | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | -39.58B | -26.53B | -53.14B | -66.18B | -74.12B | |
| Days sales outstanding | 96.55 | 109.32 | 101.35 | 107.79 | 137.93 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0.93 | 0.82 | 0.89 | 0.83 | 0.65 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.05 | 0 | 0.01 | 0.02 | 0.02 | |
| Capex per share | 0 | 0 | 1.01 | 0.56 | -0.52 |
MET Frequently Asked Questions
What is MetLife, Inc. stock symbol ?
MetLife, Inc. is a US stock , located in New york of Ny and trading under the symbol MET
What is MetLife, Inc. stock quote today ?
MetLife, Inc. stock price is $70.03 today.
Is MetLife, Inc. stock public?
Yes, MetLife, Inc. is a publicly traded company.
Company Profile
- Volume Average 3.58M
- Market Capitalization 50.71B
- Employee 45K
- CEO Mr. Michel Abbas Khalaf
- Headquarters New York,NY,US
- IPO Date 2000-04-05
-
Website
https://www.metlife.com 
MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, it provides fixed, indexed-linked, and variable annuities; and pension products; regular savings products; whole and term life, endowments, universal and variable life, and group life products; longevity reinsurance solutions; credit insurance products; and protection against long-term health care services. MetLife, Inc. was founded in 1863 and is headquartered in New York, New York.
